COMPARATIVE EFFECTIVENESS OF GEFITINIB, ERLOTINIB, AFATINIB AND CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS

被引：0
|
作者：
Lopes, Gilberto [1 ]
Haaland, Benjamin [2 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Duke Nus Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Epidermal growth factor receptor; comparative effectiveness; tyrosine kinase inhibitor; indirect comparison;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.11-015
引用
收藏
页码：S895 / S896
页数：2
相关论文
共 50 条
  • [1] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    [J]. CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [2] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Gefitinib as first line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with activating epidermal growth factor receptor (EGFR) mutations within a Western population
    Brooker, R.
    Pope, A.
    Wong, H.
    Gosney, J.
    Jain, P.
    Littler, J. A. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S830 - S830
  • [4] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
  • [5] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, de Lima G.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
  • [6] EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT
    Huicochea-Bartelt, J. L.
    Burbano, X.
    Palacios, E.
    Herran, S.
    Valencia, C.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A307 - A307
  • [7] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
    Inoue, Akira
    Kobayashi, Kunihiko
    Usui, Kazuhiro
    Maemondo, Makoto
    Okinaga, Shoji
    Mikami, Iwao
    Ando, Masahiro
    Yamazaki, Koichi
    Saijo, Yasuo
    Gemma, Akihiko
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Ikebuchi, Kenji
    Nukiwa, Toshihiro
    Morita, Satoshi
    Hagiwara, Koichi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1394 - 1400
  • [8] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations
    Krawczyk, Pawel
    Kowalski, Dariusz M.
    Ramlau, Rodryg
    Kalinka-Warzocha, Ewa
    Winiarczyk, Kinga
    Stencel, Katarzyna
    Powrozek, Tomasz
    Reszka, Katarzyna
    Wojas-Krawczyk, Kamila
    Bryl, Maciej
    Wojcik-Superczynska, Magdalena
    Glogowski, Maciej
    Barinow-Wojewodzki, Aleksander
    Milanowski, Janusz
    Krzakowski, Maciej
    [J]. ONCOLOGY LETTERS, 2017, 13 (06) : 4433 - 4444
  • [9] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ASIAN AND EUROPEAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Novello, Silvia
    Mok, Tony
    Scagliotti, Giorgio
    Finkelstein, Eric
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1179 - S1179
  • [10] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    [J]. CANCER RESEARCH, 2006, 66 (08)
12345